drugset
drugset / Trial / NCT04905602

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

NCT04905602 ↗

Phase 1 Completed 86 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.

Timeline

Start
2021-06-15
Primary completion
2023-10-09
Completion
2023-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1905 Monoclonal antibody — Subcutaneous

Indications

asthma